Cargando…

Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis

BACKGROUND: Animal models of non-alcoholic steatohepatitis (NASH) are important tools in preclinical research and drug discovery. Gubra-Amylin NASH (GAN) diet-induced obese (DIO) mice represent a model of fibrosing NASH. The present study directly assessed the clinical translatability of the model b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hansen, Henrik H., Ægidius, Helene M., Oró, Denise, Evers, Simon S., Heebøll, Sara, Eriksen, Peter Lykke, Thomsen, Karen Louise, Bengtsson, Anja, Veidal, Sanne S., Feigh, Michel, Suppli, Malte P., Knop, Filip K., Grønbæk, Henning, Miranda, Diego, Trevaskis, James L., Vrang, Niels, Jelsing, Jacob, Rigbolt, Kristoffer T. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336447/ https://www.ncbi.nlm.nih.gov/pubmed/32631250 http://dx.doi.org/10.1186/s12876-020-01356-2

Ejemplares similares

Multi-omics characterization of a diet-induced obese model of non-alcoholic steatohepatitis
por: Ægidius, Helene M., et al.
Publicado: (2020)

Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis
por: Tølbøl, Kirstine S, et al.
Publicado: (2018)

Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis
por: Tølbøl, Kirstine S., et al.
Publicado: (2018)

INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis
por: Roth, Jonathan D, et al.
Publicado: (2018)

Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source
por: Boland, Michelle L, et al.
Publicado: (2019)

Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH
por: Roth, Jonathan D., et al.
Publicado: (2019)

Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet‐induced obese and biopsy‐confirmed mouse model of NASH
por: Møllerhøj, Mathias B., et al.
Publicado: (2022)

Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH
por: Baandrup Kristiansen, Maria Nicoline, et al.
Publicado: (2019)

Integrative transcriptomic profiling of a mouse model of hypertension-accelerated diabetic kidney disease
por: Sembach, Frederikke E., et al.
Publicado: (2021)

Preserved liver regeneration capacity after partial hepatectomy in rats with non-alcoholic steatohepatitis
por: Haldrup, David, et al.
Publicado: (2018)

The Selective Peroxisome Proliferator‐Activated Receptor Gamma Modulator CHS‐131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis
por: Perakakis, Nikolaos, et al.
Publicado: (2020)

Both Elafibranor and Liraglutide Improve NAFLD / NASH but Affect Differentially the Hepatic Lipidome and Metabolome in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of NASH
por: Perakakis, Nikolaos, et al.
Publicado: (2021)

Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH
por: Perakakis, Nikolaos, et al.
Publicado: (2021)

Low Interleukin-22 Binding Protein Is Associated With High Mortality in Alcoholic Hepatitis and Modulates Interleukin-22 Receptor Expression
por: Støy, Sidsel, et al.
Publicado: (2020)

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
por: Madsen, Mette Simone Aae, et al.
Publicado: (2019)

Whole-brain activation signatures of weight-lowering drugs
por: Hansen, Henrik H., et al.
Publicado: (2021)

Global transcriptome analysis of rat hypothalamic arcuate nucleus demonstrates reversal of hypothalamic gliosis following surgically and diet induced weight loss
por: Barkholt, Pernille, et al.
Publicado: (2019)

A liver secretome gene signature-based approach for determining circulating biomarkers of NAFLD severity
por: Hagemann, Christoffer A., et al.
Publicado: (2022)

Activation and Functional Priming of Blood Neutrophils in Non-Alcoholic Fatty Liver Disease Increases in Non-Alcoholic Steatohepatitis
por: Lauszus, Johanne Sloth, et al.
Publicado: (2021)

Niemann-Pick type C2 protein supplementation in experimental non-alcoholic fatty liver disease
por: Christensen, Claus Uhrenholt, et al.
Publicado: (2018)

The IL-1β Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice
por: Cucak, Helena, et al.
Publicado: (2016)

Impaired Glucagon-Mediated Suppression of VLDL-Triglyceride Secretion in Individuals With Metabolic Dysfunction–Associated Fatty Liver Disease (MAFLD)
por: Heebøll, Sara, et al.
Publicado: (2022)

Anti-Autophagy Mechanism of Zhi Gan Prescription Based on Network Pharmacology in Nonalcoholic Steatohepatitis Rats
por: Qin, Chufeng, et al.
Publicado: (2021)

Incidental finding of non-alcoholic steatohepatitis-cirrhosis
por: Adrian, Therese, et al.
Publicado: (2022)

Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis
por: Nestor, John J., et al.
Publicado: (2022)

Alterations in hypothalamic gene expression following Roux-en-Y gastric bypass
por: Barkholt, Pernille, et al.
Publicado: (2016)

Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects
por: Laursen, Tea L, et al.
Publicado: (2019)

A Hamster Model of Diet-Induced Obesity for Preclinical Evaluation of Anti-Obesity, Anti-Diabetic and Lipid Modulating Agents
por: Dalbøge, Louise S., et al.
Publicado: (2015)

Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis.
por: Boland, Michelle L., et al.
Publicado: (2020)

Hypertrophy Dependent Doubling of L-Cells in Roux-en-Y Gastric Bypass Operated Rats
por: Hansen, Carl Frederik, et al.
Publicado: (2013)

3D quantification of changes in pancreatic islets in mouse models of diabetes type I and II
por: Roostalu, Urmas, et al.
Publicado: (2020)

Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction
por: Boland, Michelle L, et al.
Publicado: (2018)

Characterisation of Age-Dependent Beta Cell Dynamics in the Male db/db Mice
por: Dalbøge, Louise S., et al.
Publicado: (2013)

Exploring the molecular mechanism of Gan Shuang granules for the treatment of non-alcoholic steatohepatitis using network pharmacology, molecular docking, and experimental verification
por: Zhi, Guoguo, et al.
Publicado: (2023)

Reference programme: Diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 2nd Edition, 2012
por: Bendtsen, Lars, et al.
Publicado: (2012)

Outcome Measures in Clinical Trials of Patients With Myasthenia Gravis
por: Thomsen, Jan Lykke Scheel, et al.
Publicado: (2020)

Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice
por: Hansen, Henrik H., et al.
Publicado: (2021)

Involvement of mitochondrial dynamics in the segregation of mitochondrial matrix proteins during stationary phase mitophagy
por: Abeliovich, Hagai, et al.
Publicado: (2013)

Rapid Development of Non-Alcoholic Steatohepatitis in Psammomys obesus (Israeli Sand Rat)
por: Spolding, Briana, et al.
Publicado: (2014)

Correction: Experimental non-alcoholic fatty liver disease causes regional liver functional deficits as measured by the capacity for galactose metabolism while whole liver function is preserved
por: Eriksen, Peter Lykke, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v0n4g8hnute7btql1gh0r4fm7s